WO2002053583A2 - Peptides amphipathiques et leur utilisation pour transferer des substances d'interet dans les cellules - Google Patents
Peptides amphipathiques et leur utilisation pour transferer des substances d'interet dans les cellules Download PDFInfo
- Publication number
- WO2002053583A2 WO2002053583A2 PCT/FR2002/000016 FR0200016W WO02053583A2 WO 2002053583 A2 WO2002053583 A2 WO 2002053583A2 FR 0200016 W FR0200016 W FR 0200016W WO 02053583 A2 WO02053583 A2 WO 02053583A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- substance
- cells
- interest
- negative charges
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Definitions
- the present invention relates to amphipathic peptides and their use in the field of the transfer of substances of interest, more particularly nucleic acid molecules, into cells.
- nucleic acid sequences into cells constitutes the major objective of gene therapy protocols with therapeutic interest aimed at the cure of serious diseases, such as lethal gene deficiencies, cancers and infectious diseases.
- nucleic acid sequences into cells One of the essential aspects of the transfer of nucleic acid sequences into cells is the penetration of said sequences to their final target.
- This may be the nucleus for plasmid DNA, and / or the cytoplasm for oligonucleotides.
- Nucleic acids are large hydrophilic molecules. For example, a 6 kilobase plasmid represents 4.10 6 daltons. They are therefore not molecules conducive to the passage of cell membranes, and the transfer of nucleic acid sequences constitutes a major technical problem in the implementation of gene therapy methods. Many compositions useful for efficiently transfection of eukaryotic cells with selected genetic material have been described in the prior art.
- transfection vectors There are basically two main types of vectors: - natural transfection vectors, such as viruses (retroviruses, adenoviruses, adeno-associated viruses, herpes-simplex viruses) which are effective but which have limits on the use of viruses (retroviruses, adenoviruses, adeno-associated viruses, herpes-simplex viruses) which are effective but which have limits on the use of
- nucleic acids in eukaryotic cells in a more or less toxic way.
- the aim of the present invention is to offer a new vectoring system presenting these three functions in an optimal manner and not presenting
- amphipathic peptide is intended to mean peptides which have a hydrophobic pole and a hydrophilic pole. Such peptides consisting essentially of hydrophilic and hydrophobic amino acids have in particular
- the subject of the invention is therefore a peptide capable of transferring a substance of interest carrying negative charges inside the cells and / or inside the nucleus of the cells, characterized in that said peptide is an amphipathic peptide from approximately 10 to 30, preferably from 15 to 25, amino acids and corresponding to the following formula:
- L represents leucine
- .0 R represents arginine
- m is an integer between 0 and 2
- n is 1 or 2.
- Preferred peptides according to the invention correspond to the following formula: L5 (RLLR) p (L) n (R) n , in which:
- L leucine
- R represents arginine
- p is an integer between 2 and 4
- n is 1 or 2.
- a very preferred peptide according to the invention corresponds to the following formula represented in the sequence list in the appendix under the number SEQ ID NO. l: RLLRRLLRRLLRLLRR.
- the subject of the invention is also vectors capable of transporting in vitro or in vivo a substance of interest carrying negative charges inside the cells and / or inside the nucleus of the cells, said cell.
- the invention particularly contemplates as a compound capable of condensing a substance of interest carrying negative charges such as a nucleic acid, a pol lysine group comprising about at least 5 and up to 25 lysine residues.
- the invention envisages very particularly, as a compound exhibiting an affinity for cell membranes, a fatty acid chain, saturated or unsaturated, such as for example palmitoyl.
- the polylysine group or the residue of fatty acid can be coupled to the N or C-terminal end of the peptide, either directly or via a linker arm.
- the peptides of the invention and said peptides coupled to a polylysine group can be prepared by chemical synthesis or by techniques of genetic expression.
- the coupling of the fatty acid type compounds to a peptide of the invention can be carried out by chemical reactions known to those skilled in the art.
- compositions comprising a peptide or a vector as described above and a substance of interest carrying negative charges.
- Negative charges of the substance of interest in said composition is equal to or greater than 1.
- the longer the nucleic acid the higher the number of positive charges provided by the peptide to obtain maximum effect.
- compositions are useful for the preparation of pharmaceutical, cosmetic or diagnostic compositions depending on the nature of the substance of interest.
- the peptides of the invention are remarkable in that they are capable of associating by type bonds ionic with a wide variety of substance of interest and transport these into cells.
- the substance of interest carrying negative charges can be any type of chemical or biological entity carrying negative charges and whose overall charge can be positive, negative or neutral. It can be therapeutic, cosmetic, food or diagnostic substances.
- the invention is particularly interested in the vectorization of proteins and very particularly in the transfer of nucleic acid molecules into the cytoplasm and / or the nucleus of cells.
- nucleic acid molecule By nucleic acid molecule is meant both DNA and RNA molecules. It can of course be genes or parts of the gene, possibly inserted into a plasmid and placed under the control of expression sequences adapted to the transfected host. These genes or parts of the gene encode therapeutic proteins. They can also be short nucleic acid sequences, such as oligonucleotides or ribozymes, useful in antisense gene therapy strategies.
- the peptides, vectors and compositions of the invention are useful for transporting in vivo or in vitro substances of interest and very particularly nucleic acids in cells, in particular eukaryotes.
- they can make it possible to transfer nucleic acids or proteins into specific cell lines, for example in order to express a protein or to inhibit its production.
- They can be used for direct administration of the nucleic acid or protein into an organism.
- They can also be used ex vivo for the transfer of nucleic acid or protein into a specific cell to give it a new property before re-administering it to an organism.
- the invention therefore also relates to these cells comprising peptides, vectors and compositions described above.
- compositions of the invention can be used free or incorporated into particles or nanoparticles such as liposomes.
- FIG. 1 represents the migrations of plasmid DNA obtained on a retardation gel as a function of the amount of peptide associated with said DNA.
- the H-Orn-Ahx ⁇ RLLRRLLRRLLRLLRR-NH2 peptide is assembled on solid phase using an Fmoc-tBu protocol.
- the ornitine introduced in the form of Fmoc-Orn (Fmoc) -OH is released by treatment of the peptidyl resin with piperidine (20% in Dimethylformamide DMF). After rinsing with DMF the resin is incubated twice 30 min in DMF containing 6 equivalents of DIEA (Diisopropylamine) and 6 equivalents of palmitic acid chloride.
- DIEA Diisopropylamine
- the peptide is then cleaved / deprotected for 3 hours in TFA / H2O / Phenol / Triisopropylsilane 86/5/5/4.
- the Palm-Orn (Palm) -Ahx-RLLRRLLRRLLRLLRR-NH2 peptide is then purified by a series of successive precipitations, followed by exclusion chromatography, then lyophilized.
- DMRIE transfecting agent or increasing amounts of peptide are added to the plasmid (1 ⁇ g) in DMSO. After 45 min of incubation, 300 ⁇ l of Optimem medium are added and the whole is spread in 12-well plates. K562 cells are added to the plates at a density of 7.10 5 cells / well and the whole is incubated for 4 hours at 37 ° C. After incubation, 3 ml of RPMI medium containing 12.5% fetal calf serum is added and the incubation is continued for 48 hours. The cells are centrifuged, washed and incubated with a buffer of lysis. After centrifugation, the supernatant is tested for luciferase activity using the Promega Luciferase Assay System test.
- the oligonucleotide being coupled to the FITC the acquisition is done using the FL1H filter (525 nm). A histogram of the fluorescence intensity (for 1 ⁇ 10 4 cells) is obtained and the mean distribution was considered to be representative of the amount of oligonucleotide associated with 10 cells.
- Figure 1 shows the migrations obtained on a retardation gel, depending on the amount of transfection peptide. Incubation with 0.32 nmoles (0.7 ⁇ g) of peptide results in a delay in the migration of DNA and the addition of 0.8 nmoles (1.75 ⁇ g) completely stops its migration. 2) Ability of peptides to transfect plasmid DNA into K562 cells.
- the most important transfection efficiency is observed when there is an excess of about 5 neutralizing peptide charges (positive charges) compared to DNA (negative charges). These results confirm that the transfer of the gene occurs only in the presence of an excess of positive charges.
- the charge ratio 5 corresponds to a concentration of 1 ⁇ g of plasmid for 4.75 ⁇ g of peptide.
- a poly-lysine chain or two chains of a fatty acid was coupled to the peptide of the invention.
- the addition of these chains to peptide 1 allows better condensation of the plasmid DNA as well as a better interaction with the cell membrane.
- Two peptides were therefore synthesized: Peptide 2 containing poly-L-lysine and Peptide 3 containing two palmitoyls.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02710939A EP1347991A2 (fr) | 2001-01-03 | 2002-01-03 | Peptides amphipathiques et leur utilisation pour transferer des substances d'interet dans les cellules |
IL15667202A IL156672A0 (en) | 2001-01-03 | 2002-01-03 | Amphipathic peptides and their use for transferring substances of interest into cells |
CA002433606A CA2433606A1 (fr) | 2001-01-03 | 2002-01-03 | Peptides amphipathiques et leur utilisation pour transferer des substances d'interet dans les cellules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0100043A FR2818981A1 (fr) | 2001-01-03 | 2001-01-03 | Peptides amphipathiques et leur utilisation pour le transfert de substances d'interet dans les cellules |
FR01/00043 | 2001-01-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002053583A2 true WO2002053583A2 (fr) | 2002-07-11 |
WO2002053583A3 WO2002053583A3 (fr) | 2002-08-22 |
Family
ID=8858492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/000016 WO2002053583A2 (fr) | 2001-01-03 | 2002-01-03 | Peptides amphipathiques et leur utilisation pour transferer des substances d'interet dans les cellules |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1347991A2 (fr) |
CA (1) | CA2433606A1 (fr) |
FR (1) | FR2818981A1 (fr) |
IL (1) | IL156672A0 (fr) |
WO (1) | WO2002053583A2 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2834465A1 (fr) * | 2002-01-10 | 2003-07-11 | Synt Em | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central |
WO2003106491A2 (fr) * | 2002-06-18 | 2003-12-24 | Cepep Ab | Peptides penetrant dans les cellules |
WO2009046220A3 (fr) * | 2007-10-02 | 2009-11-19 | Mdrna, Inc. | Lipopeptides pour la distribution d'acides nucléiques |
US8501824B2 (en) | 2007-05-04 | 2013-08-06 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
WO2019202049A1 (fr) * | 2018-04-18 | 2019-10-24 | Universidade De Santiago De Compostela | Peptides de pénétration cellulaire |
EP4296274A1 (fr) * | 2022-06-23 | 2023-12-27 | Universidade de Santiago de Compostela | Peptides pour l'administration intracellulaire |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856435A (en) * | 1994-02-08 | 1999-01-05 | Rhone-Poulenc Rorer Sa | Nucleic acid-containing composition, its preparation and use |
WO1999037664A1 (fr) * | 1998-01-22 | 1999-07-29 | Samyang Genex Corporation | Nouveaux peptides doues d'une action biologique |
WO2000012114A1 (fr) * | 1998-09-01 | 2000-03-09 | The Trustees Of The University Of Pennsylvania | Structures peptidiques permettant de transferer des molecules dans des cellules eukariotes |
-
2001
- 2001-01-03 FR FR0100043A patent/FR2818981A1/fr active Pending
-
2002
- 2002-01-03 CA CA002433606A patent/CA2433606A1/fr not_active Abandoned
- 2002-01-03 IL IL15667202A patent/IL156672A0/xx unknown
- 2002-01-03 WO PCT/FR2002/000016 patent/WO2002053583A2/fr not_active Application Discontinuation
- 2002-01-03 EP EP02710939A patent/EP1347991A2/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856435A (en) * | 1994-02-08 | 1999-01-05 | Rhone-Poulenc Rorer Sa | Nucleic acid-containing composition, its preparation and use |
WO1999037664A1 (fr) * | 1998-01-22 | 1999-07-29 | Samyang Genex Corporation | Nouveaux peptides doues d'une action biologique |
WO2000012114A1 (fr) * | 1998-09-01 | 2000-03-09 | The Trustees Of The University Of Pennsylvania | Structures peptidiques permettant de transferer des molecules dans des cellules eukariotes |
Non-Patent Citations (3)
Title |
---|
GOTTSCHALK S ET AL.: "A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells" GENE THERAPY, vol. 3, mai 1996 (1996-05), pages 448-457, XP000577712 * |
KAMATA H ET AL.: "Amphiphilic peptides enhance the efficiency of liposome-mediated DNA-transfection" NUCLEIC ACIDS RESEARCH, vol. 22, no. 3, 11 février 1994 (1994-02-11), pages 536-537, XP002034234 * |
WYMAN TB ET AL.: "Design, Synthesis, and Characterization of a Cationic Peptide That Binds to Nucleic Acids and Permeabilizes Bilayers" BIOCHEMISTRY, vol. 36, 1997, pages 3008-3017, XP002176053 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2834465A1 (fr) * | 2002-01-10 | 2003-07-11 | Synt Em | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central |
WO2003059394A1 (fr) * | 2002-01-10 | 2003-07-24 | Synt Em | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisatin pour le traitement des maladies du systeme nerveux central |
WO2003106491A2 (fr) * | 2002-06-18 | 2003-12-24 | Cepep Ab | Peptides penetrant dans les cellules |
WO2003106491A3 (fr) * | 2002-06-18 | 2004-12-23 | Cepep Ab | Peptides penetrant dans les cellules |
US8501824B2 (en) | 2007-05-04 | 2013-08-06 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US8877729B2 (en) | 2007-05-04 | 2014-11-04 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US9339461B2 (en) | 2007-05-04 | 2016-05-17 | Marina Biotech, Inc. | Arginine-based lipids for delivery of therapeutics |
US9731016B2 (en) | 2007-05-04 | 2017-08-15 | Marina Biotech, Inc. | Tyrosine-based lipids for delivery of therapeutics |
WO2009046220A3 (fr) * | 2007-10-02 | 2009-11-19 | Mdrna, Inc. | Lipopeptides pour la distribution d'acides nucléiques |
WO2019202049A1 (fr) * | 2018-04-18 | 2019-10-24 | Universidade De Santiago De Compostela | Peptides de pénétration cellulaire |
EP4296274A1 (fr) * | 2022-06-23 | 2023-12-27 | Universidade de Santiago de Compostela | Peptides pour l'administration intracellulaire |
WO2023247781A1 (fr) * | 2022-06-23 | 2023-12-28 | Universidade De Santiago De Compostela | Peptides pour administration intracellulaire |
Also Published As
Publication number | Publication date |
---|---|
IL156672A0 (en) | 2004-01-04 |
FR2818981A1 (fr) | 2002-07-05 |
EP1347991A2 (fr) | 2003-10-01 |
CA2433606A1 (fr) | 2002-07-11 |
WO2002053583A3 (fr) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2194797C (fr) | Composition contenant des acides nucleiques, preparation et utilisations | |
Wiradharma et al. | Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect | |
CA2180872C (fr) | Composition contenant des acides nucleiques, preparation et utilisations | |
EP0809705B1 (fr) | Compositions contenant des acides nucleiques, preparation et utilisation | |
Clements et al. | A comparative evaluation of poly-l-lysine-palmitic acid and Lipofectamine™ 2000 for plasmid delivery to bone marrow stromal cells | |
CN1863558B (zh) | 具有向核内转移能力的聚精氨酸修饰的脂质体 | |
Takei et al. | Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan‐glycocalyx | |
EP2591792B1 (fr) | Composition d'administration d'acides nucléiques, composition d'excipient, composition pharmaceutique contenant la composition d'administration d'acides nucléiques ou la composition d'excipient et méthode d'administration d'acides nucléiques | |
Avila et al. | Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules | |
EP0998501B1 (fr) | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique | |
EP2925882A1 (fr) | Méthode de criblage à haut-débit pour l'identification de biomarqueurs, cibles thérapeutiques ou d'agents thérapeutiques | |
Ohmori et al. | Importance of hydrophobic region in amphiphilic structures of α-helical peptides for their gene transfer-ability into cells | |
CN104725478B (zh) | 多肽化合物、多肽化合物与siRNA的组装体及其应用 | |
Pappalardo et al. | Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes | |
EP1347991A2 (fr) | Peptides amphipathiques et leur utilisation pour transferer des substances d'interet dans les cellules | |
FR2739292A1 (fr) | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations | |
EP1135169B1 (fr) | Utilisation d'une composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide | |
CA2318512C (fr) | Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications | |
Ganbold et al. | Efficient in vivo siRNA delivery by stabilized d-peptide-based lipid nanoparticles | |
EP4124348A1 (fr) | Nanoparticules pour l'administration de cellules | |
EP0934342B1 (fr) | Composition contenant du chitosan | |
JPWO2012008361A1 (ja) | 細胞への核酸導入方法および核酸複合体 | |
CA2272637A1 (fr) | Composition transfectante utile en therapie genique associant a un virus recombinant incorporant un acide nucleique exogene, un agent de transfection non viral et non plasmidique | |
CA2323831A1 (fr) | Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations | |
FR2834465A1 (fr) | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 156672 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002229847 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002555105 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002710939 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2433606 Country of ref document: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002710939 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002710939 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |